Pub Date : 2023-02-01DOI: 10.1016/j.nano.2022.102638
Liang Wu MD , Wouter W. Woud MSC , Carla C. Baan PhD , Dennis A. Hesselink MD, PhD , Edwin van der Pol PhD , Guido Jenster PhD , Karin Boer PhD
Urinary extracellular vesicles (uEVs) are promising biomarkers for various diseases. However, many tools measuring uEVs rely on time-consuming uEV isolation methods, which could induce sample bias. This study demonstrates the detection of single uEVs without isolation using imaging flow cytometry (IFCM). Unstained urine samples contained auto-fluorescent (A-F) particles when characterized with IFCM. Centrifugation successfully removed A-F particles from the unprocessed urine. Based on the disappearance of A-F particles, a gate was defined to distinguish uEVs from A-F particles. The final readouts of IFCM were verified as single EVs based on detergent treatment and serial dilutions. When developing this protocol to measure urine samples with abnormally high protein levels, 25 mg/mL dithiothreitol (DTT) showed improved uEV recovery over 200 mg/mL DTT. This study provides an isolation-free protocol using IFCM to quantify and phenotype single uEVs, eliminating the hindrance and influence of A-F particles, protein aggregates, and coincidence events.
{"title":"Isolation-free measurement of single urinary extracellular vesicles by imaging flow cytometry","authors":"Liang Wu MD , Wouter W. Woud MSC , Carla C. Baan PhD , Dennis A. Hesselink MD, PhD , Edwin van der Pol PhD , Guido Jenster PhD , Karin Boer PhD","doi":"10.1016/j.nano.2022.102638","DOIUrl":"https://doi.org/10.1016/j.nano.2022.102638","url":null,"abstract":"<div><p>Urinary extracellular vesicles (uEVs) are promising biomarkers for various diseases. However, many tools measuring uEVs rely on time-consuming uEV isolation methods, which could induce sample bias. This study demonstrates the detection of single uEVs without isolation using imaging flow cytometry (IFCM). Unstained urine samples contained auto-fluorescent (A-F) particles when characterized with IFCM. Centrifugation successfully removed A-F particles from the unprocessed urine. Based on the disappearance of A-F particles, a gate was defined to distinguish uEVs from A-F particles. The final readouts of IFCM were verified as single EVs based on detergent treatment and serial dilutions. When developing this protocol to measure urine samples with abnormally high protein levels, 25 mg/mL dithiothreitol (DTT) showed improved uEV recovery over 200 mg/mL DTT. This study provides an isolation-free protocol using IFCM to quantify and phenotype single uEVs, eliminating the hindrance and influence of A-F particles, protein aggregates, and coincidence events.</p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"3021361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.1016/j.nano.2022.102639
Yi-Fang Wu MSc , Kai-Yan Jin MSc , Da-Peng Wang PhD, MD , Qi Lin PhD , Jun Sun MSc , Shao-Hua Su PhD, MD , Jian Hai PhD, MD
We investigated the potential effects and mechanisms of vascular endothelial growth factor (VEGF)-nanofiber membranes (NFMs) treatment in a rat model of chronic cerebral hypoperfusion (CCH). VEGF-NFMs treatment promoted angiogenesis in surgical temporal cortex and hippocampus, alleviating decreased CBF in these two cerebral regions. VEGF-NFMs application improved reduced NAA/Cr ratio, preventing neuronal loss. VEGF-NFMs sticking decreased the number of TUNEL-positive cells in surgical temporal cortex, ameliorated impaired synaptic plasticity, and inhibited the release of pro-inflammatory cytokines and the activation of microglia and astrocytes in surgical temporal cortex and hippocampus. Furthermore, BDNF-TrkB/PI3K/AKT, BDNF-TrkB/ERK and HIF-1a/VEGF/ERK pathways were involved in the treatment of VEGF-NFMs against CCH-induced neuronal injury. These results showed the neuroprotective effects of VEGF-NFMs sticking may initiate from neurovascular repairing followed by inhibition of neuronal apoptosis and neuronal and synaptic damage, eventually leading to the suppression of cognitive dysfunction, which provided theoretical foundation for further clinical transformation of VEGF-NFMs.
{"title":"VEGF loaded nanofiber membranes inhibit chronic cerebral hypoperfusion-induced cognitive dysfunction by promoting HIF-1a/VEGF mediated angiogenesis","authors":"Yi-Fang Wu MSc , Kai-Yan Jin MSc , Da-Peng Wang PhD, MD , Qi Lin PhD , Jun Sun MSc , Shao-Hua Su PhD, MD , Jian Hai PhD, MD","doi":"10.1016/j.nano.2022.102639","DOIUrl":"https://doi.org/10.1016/j.nano.2022.102639","url":null,"abstract":"<div><p>We investigated the potential effects and mechanisms of vascular endothelial growth factor (VEGF)-nanofiber membranes (NFMs) treatment in a rat model of chronic cerebral hypoperfusion (CCH). VEGF-NFMs treatment promoted angiogenesis in surgical temporal cortex and hippocampus, alleviating decreased CBF in these two cerebral regions. VEGF-NFMs application improved reduced NAA/Cr ratio, preventing neuronal loss. VEGF-NFMs sticking decreased the number of TUNEL-positive cells in surgical temporal cortex, ameliorated impaired synaptic plasticity, and inhibited the release of pro-inflammatory cytokines and the activation of microglia and astrocytes in surgical temporal cortex and hippocampus. Furthermore, BDNF-TrkB/PI3K/AKT, BDNF-TrkB/ERK and HIF-1a/VEGF/ERK pathways were involved in the treatment of VEGF-NFMs against CCH-induced neuronal injury. These results showed the neuroprotective effects of VEGF-NFMs sticking may initiate from neurovascular repairing followed by inhibition of neuronal apoptosis and neuronal and synaptic damage, eventually leading to the suppression of cognitive dysfunction, which provided theoretical foundation for further clinical transformation of VEGF-NFMs.</p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"3341947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.1016/j.nano.2022.102635
Lidia Almenara-Fuentes MSc , Silvia Rodriguez-Fernandez PhD , Estela Rosell-Mases MSc , Katerina Kachler PhD , Axel You PhD , Miriam Salvado PhD , Darja Andreev PhD , Ulrike Steffen PhD , Holger Bang PhD , Aline Bozec PhD , Georg Schett PhD , Rozen Le Panse PhD , Joan Verdaguer MD, PhD , Marti Dalmases MD, PhD , Silvia Rodriguez-Vidal BSc , Bruna Barneda-Zahonero PhD , Marta Vives-Pi PhD
Autoimmune diseases (AIDs) are caused by the loss of self-tolerance and destruction of tissues by the host's immune system. Several antigen-specific immunotherapies, focused on arresting the autoimmune attack, have been tested in clinical trials with discouraging results. Therefore, there is a need for innovative strategies to restore self-tolerance safely and definitively in AIDs. We previously demonstrated the therapeutic efficacy of phosphatidylserine (PS)-liposomes encapsulating autoantigens in experimental type 1 diabetes and multiple sclerosis. Here, we show that PS-liposomes can be adapted to other autoimmune diseases by simply replacing the encapsulated autoantigen. After administration, they are distributed to target organs, captured by phagocytes and interact with several immune cells, thus exerting a tolerogenic and immunoregulatory effect. Specific PS-liposomes demonstrate great preventive and therapeutic efficacy in rheumatoid arthritis and myasthenia gravis. Thus, this work highlights the therapeutic potential of a platform for several autoimmunity settings, which is specific, safe, and with long-term effects.
{"title":"A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens","authors":"Lidia Almenara-Fuentes MSc , Silvia Rodriguez-Fernandez PhD , Estela Rosell-Mases MSc , Katerina Kachler PhD , Axel You PhD , Miriam Salvado PhD , Darja Andreev PhD , Ulrike Steffen PhD , Holger Bang PhD , Aline Bozec PhD , Georg Schett PhD , Rozen Le Panse PhD , Joan Verdaguer MD, PhD , Marti Dalmases MD, PhD , Silvia Rodriguez-Vidal BSc , Bruna Barneda-Zahonero PhD , Marta Vives-Pi PhD","doi":"10.1016/j.nano.2022.102635","DOIUrl":"https://doi.org/10.1016/j.nano.2022.102635","url":null,"abstract":"<div><p>Autoimmune diseases (AIDs) are caused by the loss of self-tolerance and destruction of tissues by the host's immune system. Several antigen-specific immunotherapies, focused on arresting the autoimmune attack, have been tested in clinical trials with discouraging results. Therefore, there is a need for innovative strategies to restore self-tolerance safely and definitively in AIDs. We previously demonstrated the therapeutic efficacy of phosphatidylserine (PS)-liposomes encapsulating autoantigens in experimental type 1 diabetes and multiple sclerosis. Here, we show that PS-liposomes can be adapted to other autoimmune diseases by simply replacing the encapsulated autoantigen. After administration, they are distributed to target organs, captured by phagocytes and interact with several immune cells, thus exerting a tolerogenic and immunoregulatory effect. Specific PS-liposomes demonstrate great preventive and therapeutic efficacy in rheumatoid arthritis and myasthenia gravis. Thus, this work highlights the therapeutic potential of a platform for several autoimmunity settings, which is specific, safe, and with long-term effects.</p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"2891283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.1016/j.nano.2022.102629
Feiyang Deng PhD, You Han Bae PhD
Bile acid-modified nanomedicine is a promising strategy to improve oral bioavailability. However, the efficiencies of different bile acids have not been clarified. To clarify this issue, deoxycholic acid (DCA) and cholic acid (CA) and glycocholic acid (GCA) were conjugated to carboxylated polystyrene nanoparticle (CPN). The endocytosis, intracellular and transcellular transport among the NPs were compared in Caco-2 cells, and their oral pharmacokinetics profiles were studied in C57BL/6 J mice. It was found that DCPN demonstrated higher uptake and transcytosis rate. With modification by different bile acids, the transport pathways of the NPs were altered. In mice, GCPN showed the highest absorption speed and oral bioavailability. It was found that the synergic effect of hydrophobicity and ASBT affinity might lead to the difference between in vitro and in vivo transport. This study will build a basis for the rational design of bile acid-modified nanomedicines.
{"title":"Effect of modification of polystyrene nanoparticles with different bile acids on their oral transport","authors":"Feiyang Deng PhD, You Han Bae PhD","doi":"10.1016/j.nano.2022.102629","DOIUrl":"https://doi.org/10.1016/j.nano.2022.102629","url":null,"abstract":"<div><p><span><span>Bile acid-modified nanomedicine<span><span> is a promising strategy to improve oral bioavailability. However, the efficiencies of different bile acids have not been clarified. To clarify this issue, deoxycholic acid (DCA) and </span>cholic acid<span> (CA) and glycocholic acid (GCA) were conjugated to carboxylated </span></span></span>polystyrene<span> nanoparticle<span> (CPN). The endocytosis<span><span>, intracellular and transcellular transport among the NPs were compared in Caco-2 cells, and their oral </span>pharmacokinetics<span> profiles were studied in C57BL/6 J mice. It was found that DCPN demonstrated higher uptake and transcytosis rate. With modification by different bile acids, the transport pathways of the NPs were altered. In mice, GCPN showed the highest absorption speed and oral bioavailability. It was found that the synergic effect of hydrophobicity and ASBT affinity might lead to the difference between </span></span></span></span></span><em>in vitro</em> and <em>in vivo</em> transport. This study will build a basis for the rational design of bile acid-modified nanomedicines.</p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"2891284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.1016/j.nano.2022.102632
JingWen Huang MD, PhD , XiaoTing Jian M.S. , MengMeng Xu PhD , Han Wang M.S. , ZhaoHong Liao MD, PhD , HaiQiang Lan MD, PhD , LinGe Wang PhD , JiJie Hu MD, PhD , QianQian Yu PhD , Hua Liao MD, PhD
Carbon-based nanomaterials have a high specific surface area, biocompatibility, and controlled mesopore structures. These characteristics make carbon nanospheres excellent carriers for drugs, biological dyes, photosensitizers, etc. Nevertheless, little is known about the impact of topological features on the surface of carbon nanomaterials on their in vivo immunoreactivity. In this study, we fabricated mesoporous carbon nanoparticles (MCNs) and solvent-processable carbon vesicles (CVs) by high-temperature calcination. The hematoxylin and eosin (H&E) staining suggested CVs' relatively poor dispersion capacity compared to MCNs and carbon precursors (CPs), leading to more severe muscle inflammation and necrosis. Immunostaining and Fluorescence Activated Cell Sorter (FACS) analysis further showed that both MCNs and CVs triggered a transient immune response in transplanted muscle and muscle-draining lymph nodes, but did not alter muscle resistance to exogenous viruses. In conclusion, this study provides insights into how carbon nanoparticles modulate the activation of immune responses in vivo.
{"title":"Muscle cytotoxicity and immuno-reactivity analysis of the porous carbon nanospheres fabricated by high temperature calcination","authors":"JingWen Huang MD, PhD , XiaoTing Jian M.S. , MengMeng Xu PhD , Han Wang M.S. , ZhaoHong Liao MD, PhD , HaiQiang Lan MD, PhD , LinGe Wang PhD , JiJie Hu MD, PhD , QianQian Yu PhD , Hua Liao MD, PhD","doi":"10.1016/j.nano.2022.102632","DOIUrl":"https://doi.org/10.1016/j.nano.2022.102632","url":null,"abstract":"<div><p>Carbon-based nanomaterials have a high specific surface area, biocompatibility, and controlled mesopore structures. These characteristics make carbon nanospheres excellent carriers for drugs, biological dyes, photosensitizers, etc. Nevertheless, little is known about the impact of topological features on the surface of carbon nanomaterials on their in vivo immunoreactivity. In this study, we fabricated mesoporous carbon nanoparticles (MCNs) and solvent-processable carbon vesicles (CVs) by high-temperature calcination. The hematoxylin and eosin (H&E) staining suggested CVs' relatively poor dispersion capacity compared to MCNs and carbon precursors (CPs), leading to more severe muscle inflammation and necrosis. Immunostaining and Fluorescence Activated Cell Sorter (FACS) analysis further showed that both MCNs and CVs triggered a transient immune response in transplanted muscle and muscle-draining lymph nodes, but did not alter muscle resistance to exogenous viruses. In conclusion, this study provides insights into how carbon nanoparticles modulate the activation of immune responses in vivo.</p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"1567234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The complex stroke pathophysiology, like oxidative stress and inflammatory reactions, causes substantially challenged in stroke treatment. Thymoquinone (TQ) is attributed to pharmacological actions like antioxidant and anti-inflammation. Thymoquinone is chemically hydrophobic, which causes poor solubility and bioavailability. To overcome this challenge Thymoquinone niosome was applied in this in-vivo study. The results demonstrated a significant reduction in rats treated with Thymoquinone niosome compared to free Thymoquinone and control groups (SOD), (TAC), and (GPX) activities were increased in the TQN group compared to the MCAO control group. The decrease in (MDA) level was seen in the Thymoquinone niosome group compared to the MCAO control group. The inflammation factors expression rates of IL-IB, IL-6, TNFα in I/R Thymoquinone niosome group were decreased. This study indicated that Thymoquinone niosome might be utilized as a promising novel carrier to improve Thymoquinone bioavailability and therapeutic effect in treating cerebral I/R injury.
{"title":"Neuroprotective effects of niosomes loaded with thymoquinone in the cerebral ischemia model of male Wistar rats","authors":"Somayyeh Hatami Nemati Ph.D candidate , Mohammad Reza Bigdeli Ph.D , Fatemeh Mortazavi Moghadam Ph.D , Kazem Sharifi Ph.D","doi":"10.1016/j.nano.2022.102637","DOIUrl":"https://doi.org/10.1016/j.nano.2022.102637","url":null,"abstract":"<div><p>The complex stroke pathophysiology, like oxidative stress and inflammatory reactions, causes substantially challenged in stroke treatment. Thymoquinone (TQ) is attributed to pharmacological actions like antioxidant and anti-inflammation. Thymoquinone is chemically hydrophobic, which causes poor solubility and bioavailability. To overcome this challenge Thymoquinone niosome was applied in this in-vivo study. The results demonstrated a significant reduction in rats treated with Thymoquinone niosome compared to free Thymoquinone and control groups (SOD), (TAC), and (GPX) activities were increased in the TQN group compared to the MCAO control group. The decrease in (MDA) level was seen in the Thymoquinone niosome group compared to the MCAO control group. The inflammation factors expression rates of IL-IB, IL-6, TNFα in I/R Thymoquinone niosome group were decreased. This study indicated that Thymoquinone niosome might be utilized as a promising novel carrier to improve Thymoquinone bioavailability and therapeutic effect in treating cerebral I/R injury.</p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"3457444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.1016/j.nano.2023.102654
Patricia L. Nadworny PhD , William L. Hickerson MD , Holly Denise Holley-Harrison MSN/NP , David C. Bloom PhD , Tristan R. Grams BS , Terri G. Edwards BS , Gregory S. Schultz PhD , Robert E. Burrell PhD
Solutions containing Ag0 nanoclusters, Ag+1, and higher oxidation state silver, generated from nanocrystalline silver dressings, were anti-inflammatory against porcine skin inflammation. The dressings have clinically-demonstrated broad-spectrum antimicrobial activity, suggesting application of nanosilver solutions in treating pulmonary infection.
Nanosilver solutions were tested for antimicrobial efficacy; against HSV-1 and SARS-CoV-2; and nebulized in rats with acute pneumonia. Patients with pneumonia (ventilated), fungal sinusitis, burns plus COVID-19, and two non-hospitalized patients with COVID-19 received nebulized nanosilver solution.
Nanosilver solutions demonstrated pH-dependent antimicrobial efficacy; reduced infection and inflammation without evidence of lung toxicity in the rat model; and inactivated HSV-1 and SARS-CoV-2. Pneumonia patients had rapidly reduced pulmonary symptoms, recovering pre-illness respiratory function. Fungal sinusitis-related inflammation decreased immediately with infection clearance within 21 days. Non-hospitalized patients with COVID-19 experienced rapid symptom remission.
Nanosilver solutions, due to anti-inflammatory, antiviral, and antimicrobial activity, may be effective for treating respiratory inflammation and infections caused by viruses and/or microbes.
{"title":"Treatment of infection and inflammation associated with COVID-19, multi-drug resistant pneumonia and fungal sinusitis by nebulizing a nanosilver solution","authors":"Patricia L. Nadworny PhD , William L. Hickerson MD , Holly Denise Holley-Harrison MSN/NP , David C. Bloom PhD , Tristan R. Grams BS , Terri G. Edwards BS , Gregory S. Schultz PhD , Robert E. Burrell PhD","doi":"10.1016/j.nano.2023.102654","DOIUrl":"https://doi.org/10.1016/j.nano.2023.102654","url":null,"abstract":"<div><p>Solutions containing Ag<sup>0</sup> nanoclusters, Ag<sup>+1</sup>, and higher oxidation state silver, generated from nanocrystalline silver dressings, were anti-inflammatory against porcine skin inflammation. The dressings have clinically-demonstrated broad-spectrum antimicrobial activity, suggesting application of nanosilver solutions in treating pulmonary infection.</p><p>Nanosilver solutions were tested for antimicrobial efficacy; against HSV-1 and SARS-CoV-2; and nebulized in rats with acute pneumonia. Patients with pneumonia (ventilated), fungal sinusitis, burns plus COVID-19, and two non-hospitalized patients with COVID-19 received nebulized nanosilver solution.</p><p>Nanosilver solutions demonstrated pH-dependent antimicrobial efficacy; reduced infection and inflammation without evidence of lung toxicity in the rat model; and inactivated HSV-1 and SARS-CoV-2. Pneumonia patients had rapidly reduced pulmonary symptoms, recovering pre-illness respiratory function. Fungal sinusitis-related inflammation decreased immediately with infection clearance within 21 days. Non-hospitalized patients with COVID-19 experienced rapid symptom remission.</p><p>Nanosilver solutions, due to anti-inflammatory, antiviral, and antimicrobial activity, may be effective for treating respiratory inflammation and infections caused by viruses and/or microbes.</p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"3021360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Metal-organic frameworks (MOFs) have emerged as attractive candidates in cancer theranostics due to their ability to envelop magnetic nanoparticles, resulting in reduced cytotoxicity and high porosity, enabling chemodrug encapsulation. Here, FeAu alloy nanoparticles (FeAu NPs) are synthesized and coated with MIL-100(Fe) MOFs to fabricate FeAu@MOF nanostructures. We encapsulated Doxorubicin within the nanostructures and evaluated the suitability of this platform for medical imaging and cancer theranostics. FeAu@MOF nanostructures (FeAu@MIL-100(Fe)) exhibited superparamagnetism, magnetic hyperthermia behavior and displayed DOX encapsulation and release efficiency of 69.95 % and 97.19 %, respectively, when stimulated with alternating magnetic field (AMF). In-vitro experiments showed that AMF-induced hyperthermia resulted in 90 % HSC-3 oral squamous carcinoma cell death, indicating application in cancer theranostics. Finally, in an in-vivo mouse model, FeAu@MOF nanostructures improved image contrast, reduced tumor volume by 30-fold and tumor weight by 10-fold, which translated to enhancement in cumulative survival, highlighting the prospect of this platform for oral cancer treatment.
{"title":"Theranostic doxorubicin encapsulated FeAu alloy@metal-organic framework nanostructures enable magnetic hyperthermia and medical imaging in oral carcinoma","authors":"Udesh Dhawan PhD , Ching-Li Tseng PhD , Ping-Hsuan Wu MSc , Mei-Yi Liao PhD , Huey-Yuan Wang DDS , Kevin C.-W. Wu PhD , Ren-Jei Chung PhD","doi":"10.1016/j.nano.2023.102652","DOIUrl":"https://doi.org/10.1016/j.nano.2023.102652","url":null,"abstract":"<div><p><span>Metal-organic frameworks (MOFs) have emerged as attractive candidates in cancer theranostics due to their ability to envelop magnetic nanoparticles<span><span>, resulting in reduced cytotoxicity and high porosity, enabling chemodrug encapsulation. Here, FeAu alloy nanoparticles (FeAu NPs) are synthesized and coated with MIL-100(Fe) MOFs to fabricate FeAu@MOF </span>nanostructures. We encapsulated </span></span>Doxorubicin<span><span> within the nanostructures and evaluated the suitability of this platform for medical imaging and cancer theranostics. FeAu@MOF nanostructures (FeAu@MIL-100(Fe)) exhibited superparamagnetism, magnetic hyperthermia behavior and displayed DOX encapsulation and release efficiency of 69.95 % and 97.19 %, respectively, when stimulated with alternating magnetic field (AMF). In-vitro experiments showed that AMF-induced hyperthermia resulted in 90 % HSC-3 oral </span>squamous carcinoma<span> cell death, indicating application in cancer theranostics. Finally, in an in-vivo mouse model, FeAu@MOF nanostructures improved image contrast, reduced tumor volume by 30-fold and tumor weight by 10-fold, which translated to enhancement in cumulative survival, highlighting the prospect of this platform for oral cancer treatment.</span></span></p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"3342722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.1016/j.nano.2022.102644
Farah Shahjin PhD , Milankumar Patel MS , Mahmudul Hasan MPharm , Jacob D. Cohen BS , Farhana Islam BPharm , Md Ashaduzzaman BSc , Mohammad Ullah Nayan BPharm , Mahadevan Subramaniam PhD , You Zhou PhD , Irene Andreu PhD , Howard E. Gendelman MD , Bhavesh D. Kevadiya PhD
Porous polymer microspheres are employed in biotherapeutics, tissue engineering, and regenerative medicine. Porosity dictates cargo carriage and release that are aligned with the polymer physicochemical properties. These include material tuning, biodegradation, and cargo encapsulation. How uniformity of pore size affects therapeutic delivery remains an area of active investigation. Herein, we characterize six branched aliphatic hydrocarbon-based porogen(s) produced to create pores in single and multilayered microspheres. The porogens are composed of biocompatible polycaprolactone, poly(lactic-co-glycolic acid), and polylactic acid polymers within porous multilayered microspheres. These serve as controlled effective drug and vaccine delivery platforms.
{"title":"Development of a porous layer-by-layer microsphere with branched aliphatic hydrocarbon porogens","authors":"Farah Shahjin PhD , Milankumar Patel MS , Mahmudul Hasan MPharm , Jacob D. Cohen BS , Farhana Islam BPharm , Md Ashaduzzaman BSc , Mohammad Ullah Nayan BPharm , Mahadevan Subramaniam PhD , You Zhou PhD , Irene Andreu PhD , Howard E. Gendelman MD , Bhavesh D. Kevadiya PhD","doi":"10.1016/j.nano.2022.102644","DOIUrl":"https://doi.org/10.1016/j.nano.2022.102644","url":null,"abstract":"<div><p><span><span><span>Porous polymer </span>microspheres are employed in biotherapeutics, </span>tissue engineering<span><span>, and regenerative medicine. Porosity dictates cargo carriage and release that are aligned with the polymer </span>physicochemical properties<span>. These include material tuning, biodegradation, and cargo encapsulation. How uniformity of pore size affects therapeutic delivery remains an area of active investigation. Herein, we characterize six branched aliphatic hydrocarbon-based porogen(s) produced to create pores in single and multilayered microspheres. The porogens are composed of biocompatible polycaprolactone, poly(lactic-co-glycolic acid), and </span></span></span>polylactic acid<span> polymers within porous multilayered microspheres. These serve as controlled effective drug and vaccine delivery platforms.</span></p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"1567236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.1016/j.nano.2022.102647
Adam S. Mullis PhD , Scott R. Broderick PhD , Kruttika S. Phadke BS , Nathan Peroutka-Bigus PhD , Bryan H. Bellaire PhD , Krishna Rajan PhD , Balaji Narasimhan ScD
Nanoparticle carriers can improve antibiotic efficacy by altering drug biodistribution. However, traditional screening is impracticable due to a massive dataspace. A hybrid informatics approach was developed to identify polymer, antibiotic, and particle determinants of antimicrobial nanomedicine activity against Burkholderia cepacia, and to model nanomedicine performance. Polymer glass transition temperature, drug octanol-water partition coefficient, strongest acid dissociation constant, physiological charge, particle diameter, count and mass mean polydispersity index, zeta potential, fraction drug released at 2 h, and fraction release slope at 2 h were highly correlated with antimicrobial performance. Graph analysis provided dimensionality reduction while preserving nonlinear descriptor-property relationships, enabling accurate modeling of nanomedicine performance. The model successfully predicted particle performance in holdout validation, with moderate accuracy at rank-ordering. This data analytics-guided approach provides an important step toward the development of a rational design framework for antimicrobial nanomedicines against resistant infections by selecting appropriate carriers and payloads for improved potency.
{"title":"Data analytics-guided rational design of antimicrobial nanomedicines against opportunistic, resistant pathogens","authors":"Adam S. Mullis PhD , Scott R. Broderick PhD , Kruttika S. Phadke BS , Nathan Peroutka-Bigus PhD , Bryan H. Bellaire PhD , Krishna Rajan PhD , Balaji Narasimhan ScD","doi":"10.1016/j.nano.2022.102647","DOIUrl":"https://doi.org/10.1016/j.nano.2022.102647","url":null,"abstract":"<div><p><span><span><span>Nanoparticle<span> carriers can improve antibiotic efficacy by altering </span></span>drug<span> biodistribution. However, traditional screening is impracticable due to a massive dataspace. A hybrid informatics approach was developed to identify polymer, antibiotic, and particle determinants of antimicrobial </span></span>nanomedicine activity against </span><span><em>Burkholderia cepacia</em></span><span><span><span>, and to model nanomedicine performance. Polymer glass transition temperature, drug octanol-water </span>partition coefficient<span><span>, strongest acid dissociation constant, physiological charge, particle diameter, count and mass mean </span>polydispersity index, </span></span>zeta potential<span>, fraction drug released at 2 h, and fraction release slope at 2 h were highly correlated with antimicrobial performance. Graph analysis provided dimensionality reduction while preserving nonlinear descriptor-property relationships, enabling accurate modeling of nanomedicine performance. The model successfully predicted particle performance in holdout validation, with moderate accuracy at rank-ordering. This data analytics-guided approach provides an important step toward the development of a rational design framework for antimicrobial nanomedicines against resistant infections by selecting appropriate carriers and payloads for improved potency.</span></span></p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"3210033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}